VENTYX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ventyx Biosciences, Inc. and Encourages Investors to Contact the Firm
Investors have until April 30, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- Investors have until April 30, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
- Ventyx is a clinical-stage biopharmaceutical company that develops small-molecule product candidates to address a range of inflammatory diseases.
- In addition, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
- On November 6, 2023, during after-market hours, Ventyx issued a press release announcing results from the Phase 2 SERENITY Trial.